MatthewBarthMD
Pediatric Hematology & Oncology • Buffalo, NYPediatric Hematologic Oncology, Pediatric Neuro-Oncology
Clinical Associate Professor, Jacobs School of Medicine and Biomedical Sciences at University at Buffalo Pediatric Transplant and Cellular Therapy Co-Director of Pediatric Neuro-Oncology Director of Pediatric Neurofibromatosis Program
Dr. Barth is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
818 Ellicott St
Buffalo, NY 14203Phone+1 716-845-2333Fax+1 716-845-8003
Summary
- Dr. Matthew Barth is a pediatric hematologist/oncologist in Buffalo, NY and is affiliated with John R Oishei Children's Hospital and Roswell Park Comprehensive Cancer Center. He received his medical degree from SUNY Upstate Medical University and has been in practice 12 years. He is experienced in lymphoma, personalized medicine, leukemia, stem cell transplant, cellular therapy and neuro oncology.
Education & Training
University at BuffaloFellowship, Pediatric Hematology/Oncology, 2008 - 2011- University at BuffaloResidency, Pediatrics, 2005 - 2008
SUNY Upstate Medical UniversityClass of 2005
Certifications & Licensure
NY State Medical License 2008 - 2025- American Board of Pediatrics Pediatrics
- American Board of Pediatrics Pediatric Hematology-Oncology
Awards, Honors, & Recognition
- Young Investigator Award International Society of Paediatric Oncology, 2016
- Henry C. and Bertha H. Buswell Fellowship University at Buffalo, 2011-2014
- Travel Award 11th International Conference on Malignant Lymphoma, 2011
- Join now to see all
Clinical Trials
- Treatment for Advanced B-Cell Lymphoma Start of enrollment: 2013 Jan 01
- Obinutuzumab and ICE Chemotherapy in Refractory/Recurrent CD20+ Mature NHL Start of enrollment: 2015 Aug 21
Publications & Presentations
PubMed
- 1 citationsAMG176, an MCL-1 inhibitor, is active in pre-clinical models of aggressive B-cell lymphomas.Pallawi Torka, Tara Russell, Cory Mavis, Juan Gu, Paola Ghione
Leukemia & Lymphoma. 2023-06-01 - An institutional review of genomic sequencing in pediatric solid tumors.George M Turco, Ajay Gupta, Philip Monteleone, Kara M Kelly, Roger D Klein
Pediatric Blood & Cancer. 2023-06-01 - 7 citationsMolecular Evolution of Classic Hodgkin Lymphoma Revealed Through Whole-Genome Sequencing of Hodgkin and Reed Sternberg Cells.Francesco Maura, Bachisio Ziccheddu, Jenny Z Xiang, Bhavneet Bhinder, Joel Rosiene
Blood Cancer Discovery. 2023-05-01
Abstracts/Posters
- Polatuzumab Vedotin, an Antibody-Drug Conjugate Targeting CD79b, Is a Highly Active Agent Against Burkitt Lymphoma and Primary Mediastinal B-Cell LymphomaMatthew J. Barth, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- BCL-Xl Expression Is Druggable Biomarker Associated with a Poor Clinical Outcome in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)Matthew J. Barth, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Press Mentions
NCCN Guidelines Highlight ‘Complicated’ Treatment for Pediatric LymphomasJanuary 14th, 2020
Grant Support
- Scholar AwardSt. Baldrick's Foundation2013–2018
Professional Memberships
- Member
- Member
- American Society of Pediatric Hematology/OncologyMember
- International Society of Paediatric OncologyMember
- Children's Oncology GroupMember
External Links
- Women & Children's Hospital of Buffalohttp://www.wchob.org/ubmdpediatrics
- Roswell Park Cancer Institutehttps://www.roswellpark.org/
- University at Buffalo Department of Pediatricshttp://medicine.buffalo.edu/pediatrics
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
